RPG Life Sciences Targets ₹500 Crore OTC Market, Reports Q1 Results 3 days ago
RPG Life Sciences announced plans to expand into the ₹500 crore OTC pharmaceutical market in India, investing ₹200 crore in immunosuppressant drugs. The company reported Q1 financial results with revenue of ₹168.90 crore, up 2.1% year-on-year. EBITDA margin slightly decreased to 24.10%, and Profit Before Tax was ₹35.40 crore. Domestic Formulations segment showed strong growth, while International Formulations and API segments faced challenges. The company is focusing on global generics and exploring inorganic growth opportunities.
RPG Life Sciences Expands Global Reach, Reports Steady Q1 Growth 3 days ago
RPG Life Sciences Reports Q1 FY26 Results, Appoints New API Business Chief 3 days ago
RPG Life Sciences Reports 2.1% Revenue Growth in Q1 FY26, Maintains Strong EBITDA Margin 3 days ago
RPG Life Sciences Reports Stellar Q4 FY25 Results: PAT Soars 786%, Announces Special Dividend Apr 29, 2025
More news about RPG Life Sciences
28Apr 25
RPG Life Sciences Reports Stellar Q4 Results, Declares Special Dividend Amid Leadership Changes
RPG Life Sciences announced impressive Q4 FY2025 results with net profit soaring to ₹1,173.50 crore, up from ₹132.40 crore in Q4 FY2024. Revenue increased to ₹1,430.90 crore. The company declared a final dividend of ₹20 and a special dividend of ₹4 per equity share. Exceptional items included a ₹1,262.30 crore profit from land assignment and a ₹163.30 crore loss from a fire incident. Key leadership changes were announced, including the appointment of a new Managing Director.